target of 4% to 6% and its consolidated adjusted per-share earnings CAGR target of 12% to 14% for fiscal 2024 to 2026. Cardinal Health has not yet offered guidance for fiscal 2025 but expects ...
(Reuters) - Cardinal Health said on Monday its contracts with UnitedHealth Group's OptumRx, one of its largest customers, will not be renewed after they expire at the end of June, sending the drug ...
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s ...
DUBLIN, Ohio - Cardinal Health (NYSE ... consolidated non-GAAP EPS CAGR of 12% to 14% for fiscal years 2024 to 2026, based on fiscal 2023 figures. Cardinal Health's sales to OptumRx accounted ...
March 16, 2024 • Discover the latest insights in health care as we discuss the effect of endometriosis and the transformative role of artificial intelligence. Experts discuss symptoms ...
Australian engineer [John Catsoulis] developed a small module called the Scamp2 dedicated to running Forth. The focus of his Udamonic project was not only to highlight Forth, but to make a module ...
Cardinal Health said. Cardinal said it expects to partially offset the impact of losing the Optum contracts through customer additions and growth in its more profitable specialty pharmacy business.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results